Evidence map›Paper›PMID 28656554›Full record

ArticleMycopathologia2017

Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.

Rodrigo de Carvalho Santana, Letícia Aparecida Schiave, Alda Soares Dos Santos Quaglio, Cristiane Masetto de Gaitani, Roberto Martinez

Open access · greenAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Mycopathologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Cryptococcus spp. and Cryptococcosis: focusing on the infection in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022
    Review
  3. Journal of fungi (Basel, Switzerland) · 2021
    Review
  4. The status of cryptococcosis in Latin America.Memorias do Instituto Oswaldo Cruz · 2018
    Review
  5. Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
  6. Clinical and microbiological characteristics of cryptococcosis at an university hospital in China from 2013 to 2017.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rodrigo de Carvalho SantanaDepartament of Internal Medicine, Ribeirão Preto Medical School, São Paulo University, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil. santanacrod@fmrp.usp.br.
Letícia Aparecida SchiaveDepartament of Internal Medicine, Ribeirão Preto Medical School, São Paulo University, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
Alda Soares Dos Santos QuaglioDepartament of Internal Medicine, Ribeirão Preto Medical School, São Paulo University, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
Cristiane Masetto de GaitaniSchool of Pharmaceutical Sciences of Ribeirão Preto, São Paulo University, São Paulo, Brazil.
Roberto MartinezDepartament of Internal Medicine, Ribeirão Preto Medical School, São Paulo University, Av. Bandeirantes 3900, Monte Alegre, Ribeirão Preto, São Paulo, 14049-900, Brazil.
Universidade de São Paulo · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2012/51030-4
6 · The paper itself

Abstract

The treatment of cryptococcosis is hampered by inefficacy or intolerance to the recommended antifungal agents. A patient diagnosed with AIDS had multiple relapses of cryptococcal infection, which became refractory to antifungal agents during the course of therapy. During the follow-up, the patient developed renal toxicity due to amphotericin B use and non-susceptibility of isolated Cryptococcus neoformans to fluconazole was detected. Thereafter, antifungal treatment was performed exclusively with liposomal amphotericin B, reaching a cumulative dose of 19,180 mg over 46 months. The final relapse of cryptococcosis occurred during the maintenance phase with liposomal formulation in a once-weekly dose. Measurement of the minimum serum concentrations of amphotericin B, determined sequentially before and after this relapse, suggested the importance of monitoring drug levels when the liposomal formulation is used for a long period.

Indexed as

Drug Resistance, FungalAcquired Immunodeficiency SyndromeAdultAmphotericin BAntifungal AgentsCryptococcus neoformansFluconazoleHumansMaleMeningitis, CryptococcalRecurrenceSerumTreatment OutcomeAmphotericin BAntifungal AgentsFluconazoleliposomal amphotericin BAntifungal susceptibilityCryptococcal meningitisCryptococcusFluconazoleLiposomal amphotericin B

Identifiers

PMID28656554
OpenAlexW2725729160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.